DDW Reports

[Guest guest]

NATA: DDW Reports

NATAP http://natap.org/_______________________________________________

DDWDigestive Disease WeekMay 21-24, 2006, Los Angeles"...the most real-time, comprehensive, independent conference coverage on the internet..."These are reports from DDW so far posted on the NATAP website, others will be added. "Week 12 Antiviral Activity of Higher Doses of albumin interferon alfa-2b (Albuferon) Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic HCV-Infection" - (05/25/06) Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B - (05/25/06)Final Analysis of Virological Outcomes and Resistance During 5 Years of adefovir Dipivoxil Monotherapy in HBeAg-Negative Patients - (05/25/06) 96-Week Viral Suppression Data >From Two Studies Presented For BARACLUDE (entecavir) In Chronically-Infected Hepatitis B Patients - (05/24/06)Results from a Cost-Effectiveness Study Demonstrate Positive Economic Impact with PEGASYS Treatment - (05/24/06)G-CSF is safe and improves adherence and SVR in HCV patients with genotype 1 who develop Peg-IFNa-2b related severe neutropenia - (05/24/06) African-Americans' response to Interferon: preliminary results from Virahep C Study - (05/24/06) VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06) ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week - (05/23/06)HCV Protease ITMN 191, In Vitro Resistance - - (05/23/06)High Dose Albuferon -early data - (05/23/06) Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity - (05/23/06) Reliable early prediction of viral relapse by detection of minimal residual hepatitis C viremia at treatment week 12 with Sensitive HCV Viral load Test - (05/22/06) High Prevalence of Hepatitis C Virus Infection Among Russian Immigrants in the New York City Metropolitan Area: Results of A Community-Based Screening Program - (05/22/06) Noninvasive Biomarker Test for Fatty Liver - (05/22/06)Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients - (05/22/06)The prevalence of metabolic syndrome (53%) in veterans with chronic hepatitis C virus - (05/22/06)NATAP http://natap.org/